Navigation Links
Taste Receptors in the Gut Identified as New Target for Satiety and Glucose Regulation
Date:11/15/2013

SAN DIEGO, Nov. 15, 2013 /PRNewswire/ -- NaZura BioHealth today announced clinical study results indicating that activation of taste receptors in the lower gut can amplify the release of hormones involved in satiety and glucose regulation.  In an oral presentation to be made today at the Obesity Society's Annual Scientific Meeting, principal investigator Steven R. Smith, MD will describe how NaZura's proprietary Gut Sensory Modulation (GSM) technology can be used to intensify the body's natural, food-driven signals.

Delivering formulations of GRAS (Generally Recognized As Safe) dietary ingredients and FDA-approved food additives to the lower gut activates chemosensory sweet, umami and bitter receptors on enteroendocrine cells. These cells release a number of peptides including peptide YY (PYY), which signals satiety to the brain, and glucagon-like peptide-1 (GLP-1), which plays an important role in glucose regulation. The activation of taste receptors with non-nutritive agonists in effect stimulates the enteroendocrine cells to react as though a greater caloric load had been consumed. In short-term studies, NaZura has shown that formulations of sweet, umami and bitter agonists increased the body's food-driven production of PYY and GLP-1 twofold compared to placebo under various meal conditions.

"NaZura BioHealth has broken new ground with this concept of localized delivery of active compounds to the enteroendocrine cells with the goal of improving weight management and glucose control  " said Alain D. Baron, MD, president and chief executive officer of NaZura BioHealth. "As we're hearing at this week's Obesity Society meeting there remains a significant need for safe solutions to help people manage their weight."

NaZura BioHealth Poster at Obesity Society Annual Scientific Meeting

Activation of Intestinal Taste Receptors Augmented Oral Glucose Stimulated GLP-1 and PYY in Healthy Humans

  • Date and Time: Friday, November 15, 2013, 1:30 p.m. to 3:00 p.m. ET
  • Presenter: Steven R. Smith, MD, Director, Florida Hospital–Sanford-Burnham Translational Research Institute for Metabolism and Diabetes; Professor, Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute; and Chief Scientific Officer, Florida Hospital Research Services.
  • Abstract ID, Category:  T-60-OR, Oral Abstracts Track 3 – Appetite

Based on the GSM findings to date, NaZura is currently conducting a randomized, placebo-controlled, double-blind weight loss study in 240 overweight and moderately obese subjects.

About NaZura BioHealth  
NaZura BioHealth is developing consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) technology. GSMs are delivered to the lower gut where they intensify the body's natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. NaZura's lead product is Lovidia™, a dietary supplement for weight management targeted to the consumer health market.   For more information, visit www.NaZuraBio.com.

Media Contacts:
Martin Brown, NaZura BioHealth
Senior Vice President, Finance and Operations
(858) 876-1814 ext. 103
marty.brown@nazurabio.com

Pam Lord
Canale Communications
619-849-6003
pam@canalecomm.com


'/>"/>
SOURCE NaZura BioHealth
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
2. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
3. mHealth Identified as Critical Strategy in Medication Adherence Programs
4. Cord Blood Stem Cells Stored at No Cost to Families with an Identified Medical Need Provide Therapeutic Options
5. Target for potent first-strike influenza drugs identified
6. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
8. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Medbox Targets Newly Emerging $1.3 Billion Canadian Medical Marijuana Market
10. Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
11. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):